CD274 and neoplasm: While it is evident that the HR+/HER2− subgroup exhibits less immunogenicity than TNBC, studies have shown that the LumB subtype expresses higher levels of programmed death-ligand 1 (PD-L1), tumor mutational burden (TMB), and tumor-infiltrating lymphocytes (TILs), which suggests the possibility of enhancing the current standard of care using immunotherapies such as immune checkpoint inhibitors (ICIs) [5].